Recursion Pharmaceuticals... (RXRX)
NASDAQ: RXRX
· Real-Time Price · USD
5.49
-0.03 (-0.54%)
At close: Oct 03, 2025, 3:59 PM
5.46
-0.55%
After-hours: Oct 03, 2025, 07:58 PM EDT
-0.54% (1D)
| Bid | 5.47 |
| Market Cap | 2.36B |
| Revenue (ttm) | 64.44M |
| Net Income (ttm) | -648.97M |
| EPS (ttm) | -1.81 |
| PE Ratio (ttm) | -3.03 |
| Forward PE | -4.31 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 5.49 |
| Volume | 48,585,359 |
| Avg. Volume (20D) | 26,387,126 |
| Open | 5.60 |
| Previous Close | 5.52 |
| Day's Range | 5.34 - 5.70 |
| 52-Week Range | 3.79 - 12.36 |
| Beta | 0.91 |
| Ex-Dividend Date | n/a |
About RXRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RXRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RXRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsRecursion Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-4.66%
Recursion Pharmaceuticals shares are trading lower...
Unlock content with
Pro Subscription
2 months ago
+8.72%
Recursion Pharmaceuticals shares are trading higher after the company announced it acquired the joint ENPP1 inhibitor program and associated backup molecule from Rallybio.
